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Genome-wide association analysis 
of chronic lymphocytic leukaemia, 
Hodgkin lymphoma and multiple 
myeloma identifies pleiotropic risk 
loci
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Guy Pratt9, Thahira Rahman4, Chris Pepper10, Chris Fegan11, Elke Pogge von Strandmann12, 
Andreas Engert12, Asta Försti13,14, Bowang Chen13, Miguel Inacio da Silva Filho13, 
Hauke Thomsen13, Per Hoffmann15,16, Markus M. Noethen15,17, Lewin Eisele18,  
Karl-Heinz Jöckel18, James M. Allan4, Anthony J. Swerdlow1,19, Hartmut Goldschmidt20,21, 
Daniel Catovsky2, Gareth J. Morgan3, Kari Hemminki13,14 & Richard S. Houlston1,2
B-cell malignancies (BCM) originate from the same cell of origin, but at different maturation stages 
and have distinct clinical phenotypes. Although genetic risk variants for individual BCMs have been 
identified, an agnostic, genome-wide search for shared genetic susceptibility has not been performed. 
We explored genome-wide association studies of chronic lymphocytic leukaemia (CLL, N = 1,842), 
Hodgkin lymphoma (HL, N = 1,465) and multiple myeloma (MM, N = 3,790). We identified a novel 
pleiotropic risk locus at 3q22.2 (NCK1, rs11715604, P = 1.60 × 10−9) with opposing effects between 
CLL (P = 1.97 × 10−8) and HL (P = 3.31 × 10−3). Eight established non-HLA risk loci showed pleiotropic 
associations. Within the HLA region, Ser37 + Phe37 in HLA-DRB1 (P = 1.84 × 10−12) was associated 
with increased CLL and HL risk (P = 4.68 × 10−12), and reduced MM risk (P = 1.12 × 10−2), and Gly70 
in HLA-DQB1 (P = 3.15 × 10−10) showed opposing effects between CLL (P = 3.52 × 10−3) and HL 
(P = 3.41 × 10−9). By integrating eQTL, Hi-C and ChIP-seq data, we show that the pleiotropic risk loci 
are enriched for B-cell regulatory elements, as well as an over-representation of binding of key B-cell 
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transcription factors. These data identify shared biological pathways influencing the development of 
CLL, HL and MM. The identification of these risk loci furthers our understanding of the aetiological basis 
of BCMs.
Differing in their clinical phenotype, chronic lymphocytic leukaemia (CLL), Hodgkin lymphoma (HL), and 
multiple myeloma (MM) are all malignancies resulting from the unrestrained clonal expansion of B-cells at 
different stages of maturation1–4. Evidence for inherited genetic susceptibility to CLL, HL and MM has been 
provided by studies of familial risk, and more recently from genome-wide association studies (GWAS) which 
have identified risk SNPs for each tumour type5–20. While the familial risks for CLL, HL and MM are primarily 
tumour-specific21,22, there is some epidemiological evidence for shared susceptibility23–26. An example of this is 
provided by the pattern of familial risks associated with B-cell malignancies (BCMs) in Swedish populations25.
Genetic variation at a number of loci, such as 5p15 and 8q24, have been shown to influence the risk of a num-
ber of BCM and non-haematological cancers27–34. Identifying risk loci that can have such pleiotropic effects is 
important for gaining insight into shared and divergent molecular basis of different tumour types.
While conventional meta-analysis provides a powerful tool for combining distinct GWAS, this approach is 
suboptimal in the presence of disease heterogeneity, such as when SNP associations are only manifest in a specific 
subset of the diseases, or have opposing effects for different diseases. To address such shortcomings in searching 
for pleiotropic risk SNPs for BCM, we adopted the previously validated association analysis based on subsets 
(ASSET) meta-analytic approach35,36. ASSET implements an agnostic analysis exploring all possible subsets of 
studies to identify the strongest association signal, while accounting for the multiple tests required by the subset 
search, as well as any shared controls between studies. In doing so, ASSET is able to identify variants that are 
positively and negatively associated with different diseases.
Applying this statistical procedure to six BCM GWAS (two each of CLL, HL and MM) we report the identifica-
tion of a novel pleiotropic region influencing BCM risk, as well as eight non-HLA linked pleiotropic loci that have 
only previously been described in single GWAS. Within the HLA region, we report two novel coding variants in 
class II HLA proteins which have pleiotropic effects on BCM risk.
Results
Characteristics of the six GWAS are summarised in Supplementary Table 1. After applying quality control filters 
and imputation of GWAS data (see methods) we analysed over 10 million variants for pleiotropic associations in 
7,097 BCM cases and 7,324 controls of European ancestry. Figure 1 shows a Manhattan plot of the association test 
results for CLL, HL and MM.
To determine whether the global pleiotropic regions of association for pairs of BCMs occurred more 
often than expected by chance, we generated stratified quantile-quantile (Q-Q) plots to assess enrichment of 
Figure 1. Manhattan plots (−log10(P)) by chromosome. Innermost to outermost ring – chronic lymphocytic 
leukaemia (CLL)-UK1, CLL-UK2, Hodgkin lymphoma (HL)-UK, HL-GER, multiple myeloma (MM)-UK, 
MM-GER, and ASSET association test. For clarity, only data with P < 1 × 10−3 are shown.
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associations for a given tumour type conditioned on the P-value for another tumour (Supplementary Fig. 1). The 
greater departure from the expected line associated with smaller P-values observed in the Q-Q plots provides 
evidence of pleiotropic effects between CLL, HL and MM37.
To identify the specific regions across the genome that demonstrate pleiotropic effects on risk of BCM we used 
ASSET35,36. In order for candidate SNPs to be considered, they were required to meet the following criteria: (1) 
variant associations at P ≤ 5.0 × 10−8 for the ASSET test; (2) at least one other variant in the same region (within 
r2 > 0.2) with the same pleiotropic association at P ≤ 1.0 × 10−6; (3) the individual one-sided ASSET subset tests 
were significant at P < 0.01; (4) the variant is not driven by a single study; (5) the variant cannot be both positively 
and negatively associated in different datasets of the same BCM; and (6) if a variant is positively and negatively 
associated with different BCM, the 2-sided P-value must be lower than both individual 1-sided P-values. Using 
these criteria, we identified nine non-HLA regions (607 variants).
Newly identified pleiotropic risk loci. We identified a novel pleiotropic association at 3q22.2 (rs11715604, 
P = 1.60 × 10−9, Fig. 2) with opposing associations in CLL (P1-tailed = 1.97 × 10−8) and HL (P1-tailed = 3.31 × 10−3). 
rs11715604 maps to intron 1 of NCK1, which is integral to T-cell activation38,39 and regulates the PI3K/Akt path-
way40. We also identified a number of promising associations that did not reach genome-wide significance, but 
exhibited moderate effects in the different BCM (Supplementary Table 2). These included associations at 22q13.33 
(rs131821, P = 7.49 × 10−8) and 18p11.31 (rs634212, P = 5.11 × 10−5). rs131821 is intronic of NCAPH2, which is 
important in mitotic chromosome architecture41, while rs634212 is intronic of L3MBTL4, which has been impli-
cated as a tumour suppressor gene for breast cancer42.
Previously known risk loci with newly identified pleiotropic effects. We identified genome-wide 
significant pleiotropic associations (i.e. P ≤ 5.0 × 10−8) at eight non-HLA linked loci previously identified as risk 
factors for CLL, HL or MM (Table 1). The CLL risk loci at 6p21.32 (BAK1) and 6p25.3 (IRF4) were positively 
associated with HL risk11,17. In contrast the 2q13 (BCL2L11) and 11q24.1 (GRAMD1B) risk loci for CLL nega-
tively influenced MM risk5,11. The MM risk locus at 3p22.1 (ULK4) positively influenced HL7, whereas the 2p23.3 
(DTNB) risk locus for MM negatively associated with CLL7. The HL risk locus at 3p24.1 (EOMES) was positively 
associated with CLL14. The 3q26.2 (TERC) a risk factor for MM and CLL, showed a positive association with 
HL risk10,16. In addition to variation at these eight regions we observed promising pleiotropic associations at 
2q37.1 (SP110, rs150468793; rs149207840)9, 3q27 (LPP, rs4459895)6, 5q15 (ELL2, rs2546191)18, 8q24.21 (PVT1, 
rs2720680)12, 15q15.1 (BMF, rs35603048)5, and 16q24.2 (IRF8, rs4240807)9 (Table 1).
Association studies of CLL, HL and MM have demonstrated seemingly different associations between loci 
within the HLA region and risk10,43,44. To implement an ASSET analysis of the HLA region, we imputed classical 
alleles, coding variants of HLA proteins, and SNPs using the SNP2HLA software in conjunction with the Type 
1 Diabetes Genetics Consortium (T1DGC) HLA reference panel45. Figure 3 shows the unconditioned ASSET 
associations across the 3.7 Mb HLA region. 768 variants demonstrated an association for CLL, HL and MM 
at P ≤ 5.0 × 10−8. To isolate independent pleiotropic associations we performed conditional stepwise logis-
tic regression conditioning on the strongest associated variant from the 2-sided ASSET analysis. We identified 
Ser37 + Phe37 in HLA-DRB1 (Pconditional = 1.84 × 10−12), positively associated with CLL and HL (P1-tailed-conditional 
= 4.68 × 10−12) and negatively associated with MM (P1-tailed-conditional = 1.2 × 10−2). In addition, Gly70 HLA-DQB1 
(Pconditional = 3.15 × 10−10) was positively associated with CLL (P1-tailed-conditional = 3.52 × 10−3) but negatively associ-
ated with HL (P1-tailed-conditional = 3.41 × 10−9). Additionally, a promising association for Arg62 + Glu62 in HLA-A 
(Pconditional = 9.26 × 10−8) was found, and was positively associated with CLL (P1-tailed-conditional = 8.06 × 10−5) but 
negatively associated with HL (P1-tailed-conditional = 5.68 × 10−5).
Biological inference of pleiotropic risk loci. To explore whether the identified SNPs are eQTLs, we 
searched the Blood eQTL browser46, and MuTHER47 and Geuvadis/1000 Genomes48 lymphoblastoid cell line 
(LCL) datasets. In addition we examined expression data from MM plasma cells49. We found evidence for eQTLs 
(FDR adjusted P < 0.05) for nine of the pleiotropic loci in the LCL data, and four loci in the plasma cell data 
(Supplementary Table 3).
Since spatial proximity between specific genomic regions and chromatin looping interactions are central for 
regulation of gene expression50, we identified patterns of chromatin interactions at candidate pleiotropic SNPs by 
analysing Hi-C data on GM12878, as a source of B-cell information (Fig. 2 and Supplementary Fig. 2). Looping 
chromatin interactions were shown at 3q22 (rs11715604), 3p24 (rs9880772), 3q26 (rs12638862), 6p21 (rs210143) 
and 11q24 (rs4525246). The looping interactions at 3q22, implicates IL-20RB which regulates antigen-specific 
T-cell responses51. Furthermore, at 3p24, we observed looping interactions with AZI2, which contributes to the 
activation of NF-κ B52.
Across the BCM pleiotropic risk loci, we confirmed enrichment of regulatory elements in primary haemato-
poietic stem cells (P = 2.1 × 10−3) and GM12878 cells (P = 7.4 × 10−3, Supplementary Table 4)53. Analysis of 
ChIP-seq data on 82 transcription factors (TFs) showed an enrichment of binding of key B-cell transcription 
factors, including CEBPB, RXRA, and POLR3G (P < 0.05/82 = 6.10 × 10−4) (Supplementary Fig. 3). CEBPB is 
a TF that is involved in immune and inflammatory responses54, and can induce reprogramming of B-cells into 
pluripotent stem cells55. RXRA can induce B-cell differentiation56, and POLR3G is a DNA-dependent RNA pol-
ymerase III57.
Pathway analysis and construction of a susceptibility network. We performed a gene-set enrich-
ment analysis to gain insight into the biological pathways perturbed by genetic variation common to CLL, HL 
and MM, and found eight pathways related to the inflammatory response and antigen processing that showed 
enrichment (i.e. FDR adjusted P-value < 0.05; Supplementary Table 5). Following on from this analysis, we 
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investigated the inter-connectivity of the associated genes58. By constructing a network of published and pre-
dicted protein-protein interactions, protein co-localisations and protein domain similarity, we delineated two 
broad clusters – one related to BCL2, and the other related to HLA (Supplementary Fig. 4).
Discussion
Motivated by the stratified Q-Q plots, which suggested the existence of pleiotropy, we utilised genotype data from 
six datasets in British and German populations, to conduct an agnostic cross-cancer genome-wide analysis to 
identify specific pleiotropic associations for CLL, HL and MM for both HLA and non-HLA regions. We identi-
fied a number of promising associations that have strong biological plausibility, including NCK1, NCAPH2 and 
L3MBTL4. A contemporaneous analysis also used ASSET across a number of different non-BCM cancers, and 
discovered a novel risk locus at 1q22 involving breast and lung cancer59.
Our analysis also provides evidence for common and opposing effects being responsible for BCM patho-
genesis, but is not the first to identify opposing risk associations in different cancers60,61. Given that many of the 
Figure 2. (a) Forest plot of the ORs for the association between rs11715604 and BCM. Studies were weighted 
according to the inverse of the variance of the log of the OR calculated. Horizontal lines: 95% CI. Box: OR point 
estimate; box area is proportional to the weight of the study. Diamond: overall summary estimate, with CI given 
by its width. Unbroken vertical line: null value (OR = 1.0). (b) Regional plot of association and recombination 
rates. − log10(P) (y axis) of the SNPs are shown according to their chromosomal positions (x axis). The sentinel 
SNP is shown as a large circle. The colour intensity of each symbol reflects the extent of LD with the sentinel 
SNP: white (r2 = 0) through to dark red (r2 = 1.0). Genetic recombination rates, estimated from the 1000 
Genomes Project, are shown with a light blue line. Physical positions are based on NCBI build 37 of the human 
genome. Also shown are the relative positions of genes and transcripts mapping to the region of association. 
The arcs represent Hi-C promoter contacts in GM12878 cells. The colour intensity of each contact reflects the 
interaction score. The bottom track represents the chromatin-state segmentation track (ChromHMM) for 
lymphoblastoid cells using data from the HapMap ENCODE Project.
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identified risk loci harbour genes integral for immune function, it is entirely conceivable that balancing selection 
may act to ensure immune diversity and thus a selective advantage against temporal environmental risk factors 
such as infection62.
As with standard GWAS analyses ASSET may not identify the causative genetic variant at a locus. Accepting 
this caveat, many of the identified regions map to eQTL and regulatory elements in B-cells. Moreover, they feature 
an over-representation of key B-cell TF binding.
The HLA class II region has previously been implicated in multiple BCM including follicular lymphoma33,63, 
HL12 and CLL17,44. Here, we additionally show the involvement of this region in the development of MM. By 
performing a more refined imputation analysis on the HLA region, we found a variant that alters amino acid 37 
of HLA-DRB1. This change affects the electrostatic properties of the P9 binding pocket64, altering T-cell receptor 
recognition65. The second pleiotropic association at HLA region at amino acid 70 of HLA-DQB1 is located in the 
P4 binding pocket, which is also a critical residue influencing antigen T-cell receptor binding66. A previous study 
of a number of different B-cell lymphomas using over 7,000 cases also found an association in the HLA region67, 
further highlighting the importance of this region to the development of BCM. In addition to the HLA associa-
tion, we identified other associations that were independently ascertained in the BCM specific GWAS, including 
3p24.1 (EOMES) for HL14 and CLL6, and 3q26.2 (TERC) for MM10 and CLL16, thus adding confidence that ASSET 
method is able to identify common genetic components.
Although predicated on protein-protein interactions, our pathway analysis provides two core cellular func-
tions influencing BCM susceptibility. Firstly, antigen presentation/T-cell regulation, centred around HLA, and 
secondly cellular growth and apoptosis, centred around BCL2, which are interconnected through the key B-cell 
regulators, MYB and GATA368,69. BCL2 is commonly overexpressed in BCM and is relevant to tumour escape 
apoptosis70–72. It is noteworthy that Venetoclax, a BCL2 inhibitor used in treatment of CLL73, may also be effica-
cious in treating other forms of BCM74. This exemplifies that targeting pathways identified through GWAS may 
inform drug discovery initiatives75.
In conclusion, using data from six GWAS we have identified associations with multiple BCM. There are likely 
additional loci that have an effect, but their detection will require additional efforts with larger datasets. Such 
future analyses should also address the disparity in sample sizes of each of the BCM series that characterises our 
study.
Locus SNP ID Position (bp) Allele 1 Allele 2
ASSET 
2-sided  
P-value
Disease Group 1 Disease Group 2
BCM
Odds Ratio 
(CI) P-value BCM
Odds Ratio 
(CI) P-value
2p23.3 rs6546149 25629438 C G 6.27 × 10−10 CLL 1.09 (1.01–1.17) 2.14 × 10
−2 MM 0.83 (0.78–0.88) 1.15 × 10
−9
2q13 rs12711846 111856293 A G 3.48 × 10−14 CLL 1.44 (1.31–1.58) 6.37 × 10
−14 MM 0.92 (0.86–0.98) 1.53 × 10
−2
3p24.1 rs9880772 27777779 G A 7.42 × 10−9 CLL, HL 1.18 (1.11–1.24) 7.42 × 10
−9
3p22.1 rs6763508 41750989 T C 7.56 × 10−12 MM, HL 1.22 (1.16–1.30) 7.56 × 10
−12
3q26.2 rs12638862 169477506 G A 1.88 × 10−11 CLL, MM, HL
1.15 
(1.09–1.19) 1.88 × 10
−11
6p25.3 rs9392017 442357 A G 6.03 × 10−9 CLL, HL 1.22 (1.15–1.30) 6.03 × 10
−9
6p21.32 rs210143 33546837 T C 6.81 × 10−12 CLL, HL 1.24 (1.17–1.32) 6.81 × 10
−12
11q24.1 rs4525246 123395246 G C 3.37 × 10−14 CLL 1.40 (1.28–1.53) 6.33 × 10
−14 MM 0.93 (0.87–0.99) 1.50 × 10
−2
2q37.1 rs150468793;  rs149207840 231144578 T TCCTCCTG 9.63 × 10
−8 CLL, MM 1.16 (1.10–1.22) 9.63 × 10
−8
3q27.3 rs4459895 187954414 A C 1.70 × 10−7 CLL 1.12 (1.02–1.23) 1.35 × 10
−2 HL 0.76 (0.68–0.85) 6.43 × 10
−7
5q15 rs2546191 95232541 G A 4.15 × 10−7 HL 1.18 (1.07–1.29) 5.38 × 10
−4 MM 0.88 (0.82–0.93) 4.14 × 10
−5
8q24.21 rs2720680 129115217 A G 6.78 × 10−8 HL 1.27 (1.16–1.39) 1.13 × 10
−7 CLL 0.92 (0.86–0.99) 2.9 × 10
−2
15q15.1 rs35603048 40391965 C T 3.64 × 10−7 HL 1.17 (1.06–1.28) 1.23 × 10
−3 CLL 0.81 (0.74–0.89) 1.58 × 10
−5
16q24.2 rs4240807 85985361 A C 6.62 × 10−7 CLL 1.21 (1.11–1.32) 1.35 × 10
−5 HL 0.86 (0.79–0.95) 2.70 × 10
−3
Table 1.  Novel pleiotropic associations in genomic regions already identified through single disease 
genome-wide association studies. Genome-wide significant associations are shown above, and promising 
associations are below. B-cell malignancies (BCM) in bold indicate the disease the SNP was previously shown to 
be associated. Odds ratio calculated from allele 2.
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Methods
Subjects and GWAS datasets. We used data generated from GWAS of CLL, HL, and MM performed in 
European populations which have been the subject of previous publications10–12,14,16. Briefly, the MM-UK GWAS 
comprised 2,282 cases (1,060 male; mean age at diagnosis: 64 years) recruited through the UK Medical Research 
Council (MRC) Myeloma-IX and Myeloma-XI trials. The MM-GER GWAS comprised 1,508 cases (867 male; 
mean age at diagnosis: 59 years) recruited by the German Multiple Myeloma Study Group (GMMMG) coor-
dinated by the University Clinic, Heidelberg. The HL-UK GWAS comprised 622 cases ascertained through: (i) 
Figure 3. Manhattan plot representation of the step-wise conditional logistic regression of risk of BCM in 
the HLA region. (1) Unconditioned test of the HLA region. (2) Results of the HLA region after conditioning 
on rs9269081. (3) Results of the HLA region after conditioning on rs9269081 and HLA-DPB1:03. (4) Results 
of the HLA region after conditioning on rs9269081, HLA-DPB1:03 and Ser37 + Phe37 HLA-DRB1. (5) Results 
of the HLA region after conditioning on rs9269081, HLA-DPB1:03, Ser37 + Phe37 HLA-DRB1 and Gly70 
HLADQB-1. The − log10(P) of the combined logistic regression test P-values are plotted against their physical 
chromosomal position. The broken red line represents the genome-wide level of significance (P < 5 × 10−8).
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the Royal Marsden Hospital National Health Service Trust Family History study during 2004–2008 (n = 104, 63 
male; mean age at diagnosis: 38 years); and (ii) an ongoing national study of HL in females (n = 518, mean age at 
diagnosis: 23 years) conducted by the Institute of Cancer Research (ICR). The HL-GER GWAS comprised 1,001 
HL cases (597 male; mean age at diagnosis: 35 years) ascertained by the German Hodgkin Study Group during 
1998–2007. The CLL-UK1 GWAS comprised 517 cases: (i) 155 cases (95 male; mean age at diagnosis: 59 years) 
from ICLLLC; and (ii) 362 cases (269 male; mean age at diagnosis: 63 years) from the Leukaemia Research CLL-4 
trial. CLL-UK2 comprised 1,403 cases collected from two ongoing initiatives: (i) 1,111 cases collected through a 
UK national study of CLL genetics coordinated by the ICR (712 male; mean age at diagnosis: 63 years); and (ii) 
292 cases collected through the Newcastle CLL Consortium (181 male; mean age at diagnosis: 66 years) from 
patients attending six haematology units in the UK.
Collection of blood samples and clinical information from subjects was undertaken with informed written 
consent and relevant ethical review board approval at respective institutions, in accordance with the tenets of 
the Declaration of Helsinki. Specifically, approval for the CLL data was approved by the UK Multi-Research 
Ethics Committee (MREC 99/1/082). For the MM data, the Myeloma-IX trial was approved by the Medical 
Research Council Leukaemia Data Monitoring and Ethics committee (MREC 02/8/95, ISRCTN68454111), the 
Myeloma-XI trial by the Oxfordshire Research Ethics Committee (MREC 17/09/09, ISRCTN49407852), and 
the GMMMG study was approved by the University of Heidelberg Ethical Commission (229/2003, S-337/2009, 
AFmu-119/2010). For the HL data, approval was obtained from the Multi-Research Ethics Committee (MREC 
03/1/096) for the UK data, and the Ethics Committee of the University of Cologne for the German data. All meth-
ods and experimental protocols were performed in accordance with relevant guidelines and regulations.
Genotyping of cases was performed using Illumina arrays: CLL-UK1 on 317 K array, HL-UK on 660w-Quad 
BeadChip, and CLL-UK2, HL-GER and all MM samples using Omni-express arrays (Illumina, San Diego, 
CA, US). For the UK controls, we used publicly accessible data generated by the Wellcome Trust Case Control 
Consortium (WTCCC), the 1958 Birth Cohort (also known as the National Child Development Study) and UK 
Blood Service76. Genotyping of both sets of controls was conducted using Illumina Human 1.2M-Duo Custom_
v1 Array BeadChips. For the German studies we utilised controls from the Heinz Nixdorf Recall study genotyped 
using Illumina OmniExpress array77.
Full details of the genotyping of cases and quality control can be found in previously published work10,14,16. 
Briefly, general genotyping quality control assessment was as previously described78 and all SNPs presented in this 
study passed the required thresholds. Duplicate samples were used to check genotyping quality. SNPs and samples 
with < 95% SNPs genotyped were eliminated from the analyses. Genotype frequencies at each SNP were tested for 
deviation from the Hardy–Weinberg equilibrium and rejected at P < 10−5. The number of samples and variants 
that passed quality control is provided in Supplementary Table 1.
We have previously confirmed an absence of systematic genetic differences between cases and controls10,14,16. 
Prediction of the untyped SNPs was carried out using IMPUTEv2 based on a merged reference panel from 
UK10K (April 2014 release) and from the 1000 Genomes Project (phase 1 v3)79,80. Association meta-analyses 
only included markers with info scores > 0.4, imputed call rates/SNP > 0.9 and MAFs > 0.005.
Statistical analysis. The association between variants with cancer risk in each of the six GWAS was eval-
uated by logistic regression under a log additive model using SNPTEST v279. In the MM-GER study, genomic 
inflation due to population stratification was detected (λ > 1.1), so the per-allele odds ratios (ORs) were adjusted 
using principal components obtained from smartPCA81.
To investigate pleiotropy globally, we generated stratified Q-Q plots of association signals in one cancer strat-
ified by the P-values in a second cancer37, for every combination of BCM. Leftward inflation in the null line is 
indicative of a higher degree of pleiotropy between the two tumours than expected by chance.
Subset meta-analysis was conducted using the R statistical package ASSET (association analysis based on 
subsets) which explores all possible subsets of “non-null” studies to identify the strongest association signal and 
then evaluates the significance of the signal while accounting for multiple tests required by the subset search35,36. 
One-tailed tests are subsequently combined to produce a 2-sided test statistic. Although ASSET has the advantage 
of accounting for subsets of studies with no effects and/or effects in opposing directions, where a large majority 
of effects are in one direction it will have lower power compared to the conventional fixed-effect analysis. The 
number of overlapping subjects in the GWAS (i.e. controls from WTCCC76 and Heinz-Nixdorf77 controls) were 
used as a covariate when estimating standard errors35. Imputed SNPs that showed significant associations were 
genotyped using standardised Sanger sequencing methods to confirm the imputation fidelity.
HLA imputation and analysis. To determine whether specific coding variants within HLA genes con-
tributed to the diverse association signals, we imputed the classical HLA alleles (A, B, C, DQA1, DQB1, DRB1) 
and coding variants across the HLA region using SNP2HLA45. The imputation was based on a reference panel 
from the Type 1 Diabetes Genetics Consortium (T1DGC) consisting of genotype data from 5,225 individuals of 
European descent with genotyping data of 8,961 common SNPs and indel polymorphisms across the HLA region, 
and four digit genotyping data of the HLA class I and II molecules. This reference panel has been used previously 
and showed high imputation quality for the HLA region in other studies45,82,83.
To identify independent effects, dependency analyses by step-wise logistic regression were carried out by con-
ditioning on the strongest association signal in the specific BCM. The index SNP at each region was included as a 
covariate, and the association statistics were recalculated for the remaining test SNPs. This process was repeated 
until no SNPs reached the minimum level of significance. The criteria for declaring an independent effect were 
defined as P < 5 × 10−8.
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Functional prediction. LD between SNPs were calculated with VCFtools84 using data from the UK10K 
(April 2014 release) and the 1000 Genomes Project (phase 1 v3)79,80. These data were plotted using visPIG85.
To explore the epigenetic profile of genomic location associated with BCM, we used ENCODE histone modifi-
cation data and HaploReg and RegulomeDB86,87 to examine whether any of the SNPs or their proxies (i.e. r2 > 0.8 
in the 1000 Genomes EUR reference panel) annotate transcription factor binding or enhancer elements.
To examine enrichment in specific TF binding across risk loci we adapted the variant set enrichment method 
of Cowper-Sal lari et al.88 Briefly, for each risk locus, a region of strong LD (defined as r2 > 0.8 and D’ > 0.8) was 
determined, and these SNP were termed the associated variant set (AVS). TF ChIP-seq uniform peak data was 
obtained from ENCODE for the GM12878 cell line, and included data for 82 TF. For each of these marks the 
overlap of the SNP in the AVS and the binding sites was determined to produce a mapping tally. SNPs with the 
same LD structure as the risk associated SNP were randomly selected to calculate a null mapping tally. A null 
distribution was produced by repeating this process 10,000 times, and approximate P-values were calculated as 
the proportion of permutations where the null mapping tally was greater or equal to the AVS mapping tally. An 
enrichment score was calculated by normalising the tallies to the median of the null distribution. Thus the enrich-
ment score is the number of standard deviations of the AVS mapping tally from the mean of the null distribution 
tallies.
eQTL analysis. The presence of potential eQTL was investigated through the use of several public data sets, 
namely the Blood eQTL browser46 in whole blood, and MuTHER47 and Geuvadis/1000 Genomes48 in lympho-
blastoid cell lines (LCL).
For myeloma plasma cell eQTL analysis, we included a German (n = 658) and a UK (n = 183) case series 
which had been the subject of a previous eQTL analysis49 and 608 cases of a recently published US GWAS 13. 
Gene expression profiling of CD138-purified plasma cells using Affymetrix U133 2.0 plus arrays was per-
formed as described89–91. Pre-processing of expression data was done as previously published49. Briefly, we used 
the Affymetrix U133 2.0 plus array custom (CDF) (v17) mapping to Entrez genes92 as chip definition file and 
excluded microarray probes binding to polymorphic sites. Expression data were normalized using GC-RMA. 
We only included genes with log2 expression > 3.5 in at least 95% of samples of each set. After quality control 
and excluding autosomal genes, expression data for 8,505 genes was available. The filtered set was analysed using 
probabilistic estimation of expression residuals (PEER)93 to infer known and hidden intervening variables, such 
as cytogenetic subgroups.
For the Geuvadis and MM plasma cell data, the relationship between SNPs and expression of genes located 
within 1 Mb was analysed using the Matrix eQTL94 package under a linear model. In all the datasets, SNPs in 
LD (r2 > 0.8) with the potential pleiotropic associations were explored, and were included where FDR adjusted 
P < 0.05.
Network analysis. Pathway enrichment analysis was performed using the Improved Gene Set Enrichment 
Analysis for Genome-wide Association Study (i-GSEA4GWAS v2)95. This tool also performed a functional anno-
tation analysis on these pathways by identifying the top SNPs that map to the pathway genes, and determining if 
any of these SNPs fall within ENCODE peak data, namely DNase-seq peaks of open chromatin, FAIRE peaks of 
open chromatin, TFBS SPP-based peaks, TFBS PeakSeq-based peaks and Histone peaks. In addition, eQTLs were 
determined using several eQTL databases, namely eQTL Browser, GTEx and seeQTL. Common networks were 
identified using GeneMANIA58. This database collated data on protein and genetic interactions from a number of 
sources, including BioGRID, InterPro, Reactome, and Ensembl.
Promoter capture Hi-C data. To map risk SNP to interaction involving promoter contacts and iden-
tify genes involved in HL susceptibility, we analysed previously published promoter capture Hi-C data on the 
GM12878 cell line as a model B-cell96. The promoter capture Hi-C interactions were used to functionally anno-
tate GWAS SNPs to seek for evidences of looping between the SNPs and the promoters of nearby genes. Reads 
from technical replicates were combined before processing and valid pairs were identified using HICUP97. Two 
biological replicates were analysed to assure reproducibility and significant interactions were determined using 
CHiCAGO98.
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